FDA Approves Two New HER2-Targeted Lung Cancer Drugs in 2025
Sevabertinib and zongertinib win FDA approval for HER2-mutant NSCLC, expanding targeted therapy options for previously treated patients.
Summary
The FDA approved two new targeted therapies for HER2-mutant non-small cell lung cancer in 2025. Sevabertinib (Hyrnuo), approved November 19, 2025, targets locally advanced or metastatic non-squamous NSCLC with activating HER2 mutations in patients previously treated with systemic therapy. Zongertinib (Hernexeos), approved August 8, 2025, addresses unresectable or metastatic non-squamous NSCLC with HER2 tyrosine kinase domain activating mutations, also after prior systemic therapy. HER2 mutations drive roughly 2-4% of NSCLC cases and have historically lacked dedicated approved therapies. These approvals represent a meaningful expansion of the precision oncology toolkit for a patient population with limited second-line options. Both agents reflect the growing trend of biomarker-driven approvals in thoracic oncology.
Detailed Summary
HER2-mutant non-small cell lung cancer has long represented an underserved niche in thoracic oncology. Unlike HER2-amplified breast or gastric cancers, HER2-mutant NSCLC — affecting approximately 2-4% of patients — lacked dedicated FDA-approved targeted agents until recently. Two approvals in 2025 now change that landscape significantly.
Sevabertinib, marketed as Hyrnuo, received FDA approval on November 19, 2025, for adults with locally advanced or metastatic non-squamous NSCLC harboring activating HER2 mutations who have previously received systemic therapy. The approval reflects evidence that this oral tyrosine kinase inhibitor can produce meaningful responses in a biomarker-selected population that historically had to rely on chemotherapy or off-label HER2-directed agents.
Zongertinib, marketed as Hernexeos, was approved earlier on August 8, 2025, targeting patients with unresectable or metastatic non-squamous NSCLC with HER2 tyrosine kinase domain activating mutations after prior systemic therapy. Its mechanism focuses specifically on the tyrosine kinase domain, potentially offering a more precise blockade with a differentiated tolerability profile compared to broader HER2-targeting approaches.
Together, these approvals reinforce the FDA's commitment to biomarker-stratified oncology. For clinicians, they signal the need to routinely include HER2 mutation testing in advanced NSCLC workups — a practice not yet universally adopted. Patients with HER2-mutant disease who progress on first-line therapy now have two distinct FDA-cleared options to consider.
Caveats remain. Approval data details — trial designs, response rates, progression-free survival endpoints, and safety profiles — were not available in the source material reviewed. Clinical decision-making between the two agents will depend on forthcoming comparative data, tolerability profiles, and individual patient factors. Payers and treatment guidelines will also need to align rapidly to ensure access.
Key Findings
- Sevabertinib (Hyrnuo) approved Nov 19, 2025 for previously treated HER2-mutant advanced non-squamous NSCLC.
- Zongertinib (Hernexeos) approved Aug 8, 2025 for HER2 tyrosine kinase domain-mutant unresectable or metastatic NSCLC.
- Both approvals require prior systemic therapy, positioning them as second-line or later options.
- HER2 mutations affect roughly 2-4% of NSCLC patients, a historically underserved population.
- Routine HER2 mutation testing in advanced NSCLC workups is now clinically warranted.
Methodology
This summary is based on FDA drug approval records compiled through November 2025. Specific trial names, phase, sample sizes, and efficacy endpoints were not available in the source material reviewed. Approval pathways (standard vs. accelerated) were not specified in the available data.
Study Limitations
This summary is based on brief approval listing data only — full prescribing information, trial results, and safety profiles were not available in the source material. Comparative efficacy between sevabertinib and zongertinib cannot be assessed without access to the underlying clinical trial data. The source document could not be independently verified as of the published date listed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.